Parkinson"s disease: studies in nonhuman primates annual update, March, 1992. A bibliography by Jean Balch Williams

Cover of: Parkinson

Published by Primate Information Center, Regional Primate Research Center, University of Washington in Seattle .

Written in English

Read online

Subjects:

  • Parkinsonian Disorders -- Bibliography,
  • Disease Models, Animal -- Bibliography,
  • Primate Diseases -- Bibliography

Edition Notes

Includes index.

Book details

StatementJean Balch Williams.
GenreBibliography.
SeriesPrimate Information Center topical bibliographies -- 92-003
ContributionsUniversity of Washington. Primate Information Center.
The Physical Object
Pagination19 p. ;
Number of Pages19
ID Numbers
Open LibraryOL17840914M
OCLC/WorldCa26704628

Download Parkinson"s disease: studies in nonhuman primates

This chapter provides an overview of the nonhuman primate models of Parkinson's disease and experimental therapeutics. The nonhuman primate model serves as an important model for understanding the pathophysiology of the basal ganglia, evaluating new treatment modalities for neurodegenerative disorders affecting this region, especially Parkinson's disease (PD).

Indeed, in nonhuman primates and rodents, there has been no evidence for Parkinsons disease: studies in nonhuman primates book occurrence of the pathological hallmark of Parkinson's disease, namely, Lewy bodies.

In some older, MPTP-treated primates, eosinophilic inclusions were observed in the substantia nigra and locus ceruleus; however, the identity of these features remains largely by: 7. Because we believe that only nonhuman primates accurately mimic the motor expression of PD, in our opinion, these are the only animals that are optimal for such studies.

MPTP mouse models for instance fail to replicate symptomatic manifestation of by: Pathophysiology The establishment of a model of parkinsonism through the administration of Parkinsons disease: studies in nonhuman primates book to nonhuman primates has provided important insights into new therapeutic strategies.

A typical parki. Publisher Summary. This chapter provides an overview of the neurotoxin-based nonhuman primate models of Parkinson's disease (PD). Recent studies on PD models have focused on the neurotoxin 1-methylphenyl-1,2,3,6-tetrahydropyridine (MPTP). The specific neurotoxic actions of MPTP are produced when it is metabolized by monoamine oxidase B into 1-methyl-4 Cited by: 1.

The available evidence from human and nonhuman primate studies using behavioral, neuroimaging, neurochemical, and neuropathological end points provides strong support to the hypothesis that, although excess levels of Mn accumulation in the brain results in an atypical form of parkinsonism, this clinical outcome is not associated with the degeneration of nigrostriatal.

It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease. Key Features Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease. This administration strategy will then be used to assess efficacy of trehalose in an alpha-synuclein-based non-human primate model of PD.

Relevance to Diagnosis/Treatment of Parkinson’s Disease: Trehalose could be used as orally-administered therapy to slow or reverse the progression of PD. The study results suggest that HE should be investigated in human clinical trials for Parkinson’s disease.

Presentations & Publications Ingrid Philippens, Guus Baarends, Fred Batenburg and Clarence Ahlem. Anti-Parkinson and anti-L-Dopa induced dyskinesia efficacy of HE in a MPTP non-human primate. Parkinson disease represents a research problem for which monkey studies can be justified.

It is a poorly understood and often fatal disease affecting millions of people worldwide for which there are only palliative treatments. In the first study published in May in Science Advances, we show that dopaminergic neurodegeneration can be induced in non-human primates by both, small and large aggregates of a-synuclein.

In contrast, experiments in rodents, used in 85% of studies, show that small a -synuclein aggregates do not induce neurodegeneration. The combination of nonhuman primate behavior, pharmacology and state-of-the-art brain imaging using PET will provide the foundation for future studies aimed at developing behavioral and pharmacological treatments for drug addiction in humans.

Several nonhuman primate studies and clinical trials have been performed to evaluate the potential of DAT inhibitors for PD. In this article, we review nonhuman primate studies and clinical trials, we summarize the current knowledge of DAT inhibitors in PD, and we propose a hypothesis as to how tailoring the selectivity of DAT inhibitors might maximize the benefits of DAT inhibition in PD.

Internationally recognized biomedical investigators describe in detail the major techniques employed in molecular and cellular studies of Parkinson's disease and basal ganglia function.

Widely varied methods are covered, including genetic analyses, molecular pathogenetic investigations of dopaminergic neuronal degeneration, biochemical studies of nigro-striatal neural circuitry, and molecular. 1. Introduction. The aim of this review is to offer an ethical point of view on the use of non-human primates in neurobiological studies.

We have chosen the study of Parkinson's disease (PD) as a case study, and our methodological framework will be provided by the 3R principle originally proposed by Russell and Burch (). In general, we feel that the experimental work carried out on.

Rodent and nonhuman primate models are among the many valuable animal models used to investigate important, specific questions about the disorder. One common rodent and nonhuman primate model uses the neurotoxin MPTP (1-methylphenyl-1, 2, 3, 6 tetrahydropyridine).

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease.

This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and. Similarly, close interaction between human and monkey studies was also vital to the development of the parkinsonian model in the macaque which led to the discovery that deep brain stimulation of a tiny brain structure, the subthalamic nucleus, was an effective therapy for the motor disorders associated with Parkinson’s disease, research that was recognised by the Lasker Award in.

Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials J Pharmacol Exp Ther. Jun;(3) doi: /jpet   Due to their close phylogenetic proximity to humans, nonhuman primates (NHPs) provide the most accurate models for such preclinical studies.

Of particular relevance to transplantation of stem cell-derived neurons into the brain for the treatment of Parkinson's disease (PD), NHPs accurately mimic key neuroanatomical, neurophysiological. Introduction to: Neurotoxin-based nonhuman primate models of Parkinson\'s disease \/ Zhiming Zhang and Don Marshall Gash ; System level physiology of the basal ganglia, and pathophysiology of Parkinson\'s disease \/ T.

Wichmann and M.R. Delong ; Neuroprotection for Parkinson\'s disease: clinically driven experimental design in non-human. Parkinson’s disease is a progressive neurodegenerative disease increasingly affecting our aging population.

Remarkable advances have been made in developing novel therapies to control symptoms, halt or cure the disease, ranging from physiotherapy and small molecules to cell and gene therapy.

This progress was enabled by the existence of reliable animal models. The nonhuman primate. An experimental model of Parkinson’s in non-human primates leads to the accumulation of iron — known to contribute to the underlying causes of the disease — in a brain area linked to motor control.

This metal accumulation can be detected using a neuroimaging technique called susceptibility-weighted imaging, according to recent research.

The study, titled “The role of iron in Parkinson. Taken together, our study provides invaluable primate data exploring the role of the gut-brain axis in the initiation and propagation of Parkinson's disease pathology and should open the door to the development and testing of new therapeutic approaches aimed at interfering with the development of sporadic Parkinson's disease.

These studies also show the co-existence of beta amyloid and α-synuclein pathology possibly suggesting common underlying pathogenic mechanisms between Alzheimer’s disease and PD. The sirtuins are members of the histone deacetylase family of proteins that play a role in the regulation of the cell cycle and the promotion of cell survival.

Objective/Rationale:This project will aim to establish the behavioral and neuroanatomical correlates of injecting a viral vector that overexpresses the gene for alpha-synuclein into the brains of non-human primate pre-clinical models of PD.

Alpha-synuclein is a protein whose mutation or overexpression is believed to play a role in Parkinson’s disease in humans. These data suggest that this compound may be useful for the treatment of levodopa-induced abnormal involuntary movements in Parkinson's disease.

Further studies in non-human primates are important to evaluate this possibility. Quik is currently doing further work to identify the optimal agonists for reducing dyskinesias. Bartus RT et al () Bioactivity of AAV2-neurturin gene therapy (CERE): differences between Parkinson's disease and nonhuman primate brains.

Mov Disord. 26(1); Kordower JH, Emborg ME, Bloch J et al () Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science   Rodent studies are not described in this review because, unlike non-human primates, they lack behavioral similarities to humans and are less sensitive to Mn than are humans and nonhuman primates.

Nonhuman primates have improved our understanding of the effects of Mn on motor function, in vivo brain chemistry, and neuropathology (Table 4).

Nonhuman primates represent only about one third of one percent of animals used in biomedical research. Humane Care T he California National Primate Research Center is committed to the humane care and use of animals used in research and endorses Russell and Burch’s concepts of the Three R’s.

Parkinson's disease is characterized by the progressive loss of specific cells of the brain region called substantia nigra that produce the chemical messenger dopamine. The current mainstay therapy is the administration of drugs that mimic dopamine action.

Yet as the disease progresses they lose efficacy, and disabling side effects appear. A different strategy is the administration of. In this study, a separate cohort of non-human primates was dosed with high doses of MPTP and levodopa in order to cause Parkinson’s-like motor impairments and levodopa-induced dyskinesia.

After motor impairments were established, the non-human primates were dosed with NYX and assessed on scales measuring activity, Parkinsonian disability. New vaccines protect against COVID in non-human primates, study finds Experimental COVID vaccine protects upper and lower airways in nonhuman primates.

Nonhuman primates have made significant contributions to the study of hepatitis, malaria, respiratory viral diseases, Parkinson’s disease, stem cell transplantation, and gene therapy.

In addition to biomedical research for advancement of human health, the NPRCs conduct research to help improve the physical health, psychological well-being and. More information: KS Corbett et al. Evaluation of the mRNA vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine DOI: /NEJMoa ().

Journal. Non-Human Primate Non-human primates (NHPs) play a unique role in biomedical researches because of their close phylogenetic proximity to humans. Primates are increasingly used, while researchers continue to promote the development of novel non-human primate models to mimic a variety of human diseases and conditions.

Through the course of over three decades, nonhuman primate (NHP) studies on cell-based therapies (CBTs) for Parkinson's disease (PD) have provided insight into the feasibility, safety and efficacy of the approach, methods of cell collection and preparation, cell viability, as well as potential brain targets.

Career. In William Langston was head of neurology at Santa Clara Valley Medical Center when he made a major breakthrough in the research of Parkinson's Disease as a result of several incidents detailed in the book The Case of the Frozen Addicts.

Langston continued research into Parkinson's Disease and became an internationally known neuroscientist. These studies, along with supporting data accrued at UCSF, would enable compilation of an IND.

If accepted by the FDA, we would be in a position to undertake a well-designed, NIH-supported clinical study of the safety and efficacy of AAV2-GDNF gene therapy for Parkinson’s disease. Lead Collaborator. University of California, San Francisco.

Here we review functional imaging and neurophysiological evidence for the preclinical and clinical use of electroacupuncture, a non-pharmaceutical-based therapeutic strategy, to relieve parkinsonian symptoms. Outcomes from those studies provide evidence that the effect of electroacupuncture can be objectively measured in nonhuman primate models of Parkinson’s disease and in patients with.

Experiments involving non-human primates (NHPs) include toxicity testing for medical and non-medical substances; studies of infectious disease, such as HIV and hepatitis; neurological studies; behavior and cognition; reproduction; genetics; and 65, NHPs are used every year in the United States, and around 7, across the European Union.Nonhuman primate models enable the study of human cognitive processes and complex behaviors that are essential to understanding neurodevelopmental and psychiatric disorders (Gordon, Okano, Roberts).

A transgenic marmoset model of Parkinson’s disease has enabled the study of mechanisms of sleep dysregulation in humans starting at the prodromal. NYX is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease deficits in a non-human primate model of Parkinson.

14288 views Thursday, November 19, 2020